IRC 004 - Tamiflu (Oseltamivir) Versus Placebo Study
Brief Study Description: IRC 004 is currently enrolling volunteers to participate in a study of oseltamivir (Tamiflu) vs. placebo in the treatment of influenza. Patients who have a confirmed case of influenza infection and are considered at low risk for developing complications will be randomized to receive either Tamiflu or placebo.
The study aims to determine if treatment with Tamiflu will show a decrease in the amount of the virus detected in patients, and also to understand if the change in the amount of virus present is associated with changes in flu symptoms during the course of illness and treatment. Tamiflu is licensed by the FDA to treat influenza and is recommended for use in patients who are at high risk of developing complications.
Enrollment to IRC 004 is closed in the USA and Argentina.
Additional information about this trial can be found on the ClinicalTrials.gov website, under the title: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults